He Li

He Li began their work experience in 2008 as a Visiting Scholar at the Department of Biochemistry, Chinese University of Hong Kong. From 2011 to 2012, they worked as a Postdoctoral Researcher at the Samuel Roberts Noble Foundation, where they focused on cloning and expression of sugar transporter family (SWEET) members. They then joined the Institute for Cardiovascular Prevention, LMU Munich as a Postdoctoral Researcher from 2013 to 2016. In 2016, He Li started working at ChemPartner as a Senior Scientist, managing a group of scientists and overseeing SPR and BLI-based assays. From 2018 to 2020, they worked at Harbour Biomed as an Associate Principal Scientist, before becoming a Principal Scientist in October 2020. In this role, He Li managed assays and conducted rational design/engineering of antibodies.

He Li completed a Bachelor's Degree in Bioengineering from Xi'an Jiaotong University from the years 2000 to 2004. Following that, from 2004 to 2011, they attended the Institute of Biophysics at the Chinese Academy of Sciences and obtained a Doctor of Philosophy (Ph.D.) degree in Biophysics.